Medivir’s CTCL drug remetinostat yields positive data in phase II study

This article was originally published here

Medivir has reported positive data from its phase II clinical trial of the topical, skin-directed histone deacetylase (HDAC) inhibitor, remetinostat, in early stage Cutaneous T-cell Lymphoma patients.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply